Cyclo Therapeutics Inc. (CYTH)

Name: Cyclo Therapeutics Inc. (CYTH) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Cyclo Therapeutics Inc. (CYTH)

Stock Card

$0.72

$0.00 (0.00%)

As on 27-Mar-2025 09:30EDT

Market cap

$24 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

P/B Ratio

59.1

Div. Yield

0 %

Cyclo Therapeutics (CYTH) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.72 High: 0.72

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-226.6 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.5
Debt to Equity

0.2
Book Value

$0.2
EPS

$-0.7
Face value

--
Shares outstanding

32,736,300

10 Years Aggregate

CFO

$-73.26 Mln

EBITDA

$-80.04 Mln

Net Profit

$-81.70 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Cyclo Therapeutics (CYTH)	22.1	-6.3	26.4	-48.5	-36.8	-49.1	-35.1
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 27-Mar-2025 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
Cyclo Therapeutics (CYTH)	-62.6	12.0	-61.9	-14.3	-87.2	-57.1	128.6
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Cyclo Therapeutics (CYTH)

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta... cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Cyclo Therapeutics, Inc. is a subsidiary of Rafael Holdings, Inc. Read more

CEO & Director

Mr. N. Scott Fine
CEO & Director

Mr. N. Scott Fine
Headquarters

Gainesville, FL
Website

https://cyclotherapeutics.com

FAQs for Cyclo Therapeutics (CYTH)

What is the current share price of Cyclo Therapeutics Inc (CYTH) Today?

The share price of Cyclo Therapeutics Inc (CYTH) is $0.72 (NASDAQ) as of 27-Mar-2025 09:30 EDT. Cyclo Therapeutics Inc (CYTH) has given a return of -36.77% in the last 3 years.

What is the current PB & PE ratio of Cyclo Therapeutics Inc (CYTH)?

Since, TTM earnings of Cyclo Therapeutics Inc (CYTH) is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	-0.85	3.56
2023	-1.97	8.31
2022	-0.79	16.36
2021	-1.68	1.53
2020	-2.60	2.22

What is the 52 Week High and Low of Cyclo Therapeutics Inc (CYTH)?

The 52-week high and low of Cyclo Therapeutics Inc (CYTH) are Rs -- and Rs -- as of 02-Sep-2026.

What is the market cap of Cyclo Therapeutics Inc (CYTH)?

Cyclo Therapeutics Inc (CYTH) has a market capitalisation of $ 24 Mln as on 27-Mar-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Cyclo Therapeutics Inc (CYTH)?

Before investing in Cyclo Therapeutics Inc (CYTH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.